Abstract
In eastern Europe, the high prevalence rates of HIV and the hepatitis C virus (HCV) are concentrated among injecting drug users (IDUs). Harm reduction programmes such as needle and syringe programmes and opioid substitution therapy (OST) have been shown to be effective in preventing these infections. However, structural barriers can limit their effectiveness by hindering access.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Central European Journal of Public Health |
Vol/bind | 17 |
Udgave nummer | 4 |
Sider (fra-til) | 191-7 |
Antal sider | 7 |
ISSN | 1210-7778 |
Status | Udgivet - 1 dec. 2009 |